【制药网 行业动态】根据国家药品监督管理局药品审评中心(CDE)网站 7 月 9 日公示,两款创新药 —— 百济神州的注射用塔拉妥单抗和艾力斯的甲磺酸伏美替尼片,拟被纳入优先审评品种。这一消息为相关癌症患者带来了新的希望,有望加速这两款药物的上市进程,为临床治疗提供更多有效的选择。百济神州的注射用塔拉妥单抗此次拟纳入优先审评,用于既往接受过至少 2 线治疗(包括含铂化疗)失败的广泛期小细胞肺癌(...
Source Link【制药网 行业动态】根据国家药品监督管理局药品审评中心(CDE)网站 7 月 9 日公示,两款创新药 —— 百济神州的注射用塔拉妥单抗和艾力斯的甲磺酸伏美替尼片,拟被纳入优先审评品种。这一消息为相关癌症患者带来了新的希望,有望加速这两款药物的上市进程,为临床治疗提供更多有效的选择。百济神州的注射用塔拉妥单抗此次拟纳入优先审评,用于既往接受过至少 2 线治疗(包括含铂化疗)失败的广泛期小细胞肺癌(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.